ACM derived from OGJ patients with early-stage tumours possessed higher levels of IL-5, which can have a dichotomous role in either inhibiting or promoting Th1 immunity according to the evidenced-based literature (Hung et al. 1998; Ellyard et al. 2007). This evidence concerns the gene IL5 and neoplasm.